Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 168 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1)
- The report reviews Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Overview 10
Therapeutics Development 11
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Stage of Development 11
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Therapy Area 12
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Indication 13
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Products Glance 16
Late Stage Products 16
Early Stage Products 17
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Companies 18
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Universities/Institutes 30
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Therapeutics Assessment 32
Assessment by Monotherapy/Combination Products 32
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 39
AB Science SA 39
Advenchen Laboratories, LLC 41
Amgen Inc. 42
ArQule, Inc. 43
Astellas Pharma Inc. 44
AstraZeneca Plc 45
AVEO Pharmaceuticals, Inc. 46
Bayer AG 47
Boehringer Ingelheim GmbH 48
Bristol-Myers Squibb Company 49
CASI Pharmaceuticals Inc. 50
Celon Pharma Sp. z o.o. 51
Debiopharm International SA 52
Eddingpharm 53
Eisai Co., Ltd. 54
Eli Lilly and Company 56
Evotec AG 57
Hutchison MediPharma Limited 58
Incyte Corporation 59
Johnson & Johnson 60
Les Laboratoires Servier SAS 61
Merck KGaA 62
Novartis AG 63
Principia Biopharma Inc. 65
Vichem Chemie Research Ltd. 66
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Drug Profiles 67
ARQ-087 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
ASP-5878 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
AV-370 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
AZD-4547 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
B-701 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
BAY-1163877 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
BMS-986036 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
CPL-043 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Debio-1347 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Drugs to Inhibit FGFR3 for Bladder Cancer - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
E-7090 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
EDP-317 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
ENMD-2076 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
erdafitinib - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
HMPL-453 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
INCB-54828 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
infigratinib - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
lenvatinib mesylate - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
lucitanib - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
LY-2874455 - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
masitinib - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
nintedanib - Drug Profile 123
Product Description 123
Mechanism Of Action 123
R&D Progress 123
pazopanib hydrochloride - Drug Profile 131
Product Description 131
Mechanism Of Action 131
R&D Progress 131
pazopanib hydrochloride + pembrolizumab - Drug Profile 137
Product Description 137
Mechanism Of Action 137
R&D Progress 137
PRN-1371 - Drug Profile 138
Product Description 138
Mechanism Of Action 138
R&D Progress 138
Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 139
Product Description 139
Mechanism Of Action 139
R&D Progress 139
Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 140
Product Description 140
Mechanism Of Action 140
R&D Progress 140
S-49076 - Drug Profile 141
Product Description 141
Mechanism Of Action 141
R&D Progress 141
Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile 142
Product Description 142
Mechanism Of Action 142
R&D Progress 142
sprifermin - Drug Profile 143
Product Description 143
Mechanism Of Action 143
R&D Progress 143
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Dormant Projects 145
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Discontinued Products 149
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Featured News & Press Releases 152
Jun 06, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended the filing of masitinib in ALS for conditional marketing authorization 152
Jun 06, 2016: Principia Biopharma Announces Presentation of Initial Clinical Data on PRN1371 at 2016 American Society of Clinical Oncology Annual Meeting 152
Jun 01, 2016: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma 153
May 30, 2016: AB Science will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21St Congress of the European Hematology Association 153
May 24, 2016: Eisai To Present on Lenvima at 52nd Annual Meeting of the American Society of Clinical Oncology 154
May 16, 2016: U.S. FDA Approves additional indication for Eisai anti cancer agent LENVIMA in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma 155
May 16, 2016: New Presentations at ATS 2016 Reinforce OFEV (nintedanib) Efficacy, Safety and Tolerability Across Range of Patients with idiopathic pulmonary fibrosis 156
May 12, 2016: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC) 158
May 09, 2016: LUME-Meso trial enrols first patient: Boehringer Ingelheim's new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma 158
May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis 159
Apr 20, 2016: Eisai Announces Non-Clinical Research Findings At Aacr 107Th Annual Meeting Regarding Combination Of Anticancer Agent Lenvatinib With Everolimus 160
Apr 15, 2016: Debiopharm International announces presentation at AACR of non-clinical data relating to its targeted investigational compound Debio 1347/CH5183284, a selective FGFR 1,2,3 inhibitor 160
Apr 12, 2016: Highly Anticipated New Treatment Option Now Available for Canadians with Select Type of Thyroid Cancer 161
Apr 11, 2016: Masitinib in Amyotrophic Lateral Sclerosis (ALS) 162
Apr 06, 2016: AB Science Will Host Live Webcast On Phase 3 Interim Analysis In ALS On 8 April 2016, 165
Appendix 167
Methodology 167
Coverage 167
Secondary Research 167
Primary Research 167
Expert Panel Validation 167
Contact Us 167
Disclaimer 168

List of Tables

Number of Products under Development for, H1 2016 11
Number of Products under Development by Therapy Area, H1 2016 12
Number of Products under Development by Indication, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Early Stage Products, H1 2016 17
Number of Products under Development by Companies, H1 2016 18
Number of Products under Development by Companies, H1 2016 (Contd..1) 19
Products under Development by Companies, H1 2016 20
Products under Development by Companies, H1 2016 (Contd..1) 21
Products under Development by Companies, H1 2016 (Contd..2) 22
Products under Development by Companies, H1 2016 (Contd..3) 23
Products under Development by Companies, H1 2016 (Contd..4) 24
Products under Development by Companies, H1 2016 (Contd..5) 25
Products under Development by Companies, H1 2016 (Contd..6) 26
Products under Development by Companies, H1 2016 (Contd..7) 27
Products under Development by Companies, H1 2016 (Contd..8) 28
Products under Development by Companies, H1 2016 (Contd..9) 29
Number of Products under Investigation by Universities/Institutes, H1 2016 30
Products under Investigation by Universities/Institutes, H1 2016 31
Assessment by Monotherapy/Combination Products, H1 2016 32
Number of Products by Stage and Mechanism of Action, H1 2016 34
Number of Products by Stage and Route of Administration, H1 2016 36
Number of Products by Stage and Molecule Type, H1 2016 38
Pipeline by AB Science SA, H1 2016 39
Pipeline by Advenchen Laboratories, LLC, H1 2016 41
Pipeline by Amgen Inc., H1 2016 42
Pipeline by ArQule, Inc., H1 2016 43
Pipeline by Astellas Pharma Inc., H1 2016 44
Pipeline by AstraZeneca Plc, H1 2016 45
Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 46
Pipeline by Bayer AG, H1 2016 47
Pipeline by Boehringer Ingelheim GmbH, H1 2016 48
Pipeline by Bristol-Myers Squibb Company, H1 2016 49
Pipeline by CASI Pharmaceuticals Inc., H1 2016 50
Pipeline by Celon Pharma Sp. z o.o., H1 2016 51
Pipeline by Debiopharm International SA, H1 2016 52
Pipeline by Eddingpharm, H1 2016 53
Pipeline by Eisai Co., Ltd., H1 2016 54
Pipeline by Eli Lilly and Company, H1 2016 56
Pipeline by Evotec AG, H1 2016 57
Pipeline by Hutchison MediPharma Limited, H1 2016 58
Pipeline by Incyte Corporation, H1 2016 59
Pipeline by Johnson & Johnson, H1 2016 60
Pipeline by Les Laboratoires Servier SAS, H1 2016 61
Pipeline by Merck KGaA, H1 2016 62
Pipeline by Novartis AG, H1 2016 63
Pipeline by Principia Biopharma Inc., H1 2016 65
Pipeline by Vichem Chemie Research Ltd., H1 2016 66
Dormant Projects, H1 2016 145
Dormant Projects (Contd..1), H1 2016 146
Dormant Projects (Contd..2), H1 2016 147
Dormant Projects (Contd..3), H1 2016 148
Discontinued Products, H1 2016 149
Discontinued Products (Contd..1), H1 2016 150
Discontinued Products (Contd..2), H1 2016 151